ONIVYDE combination therapy for advanced pancreatic cancer in China
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study looks at how safe and effective the drug ONIVYDE (liposomal irinotecan) is when given with two other chemotherapy drugs (5-FU and leucovorin) for people with pancreatic cancer that has spread. It follows patients who are already being prescribed this treatment by their doctor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your doctor has decided to prescribe you ONIVYDE (liposomal irinotecan) as part of your treatment plan.
- You have a type of pancreatic cancer (adenocarcinoma) that has spread to other parts of the body (metastatic).
- You have either tried a chemotherapy called gemcitabine and it didn't work, or your doctor says you cannot take gemcitabine for medical reasons.
- You have not had a severe allergic reaction to ONIVYDE or similar drugs.
- You do not have new or worsening lung symptoms like shortness of breath, cough, or fever that are being checked for a lung condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests ONIVYDE® (a type of irinotecan drug) combined with carboplatin in people with advanced or metastatic gastroenteropancreatic poorly differentiated neuroendocrine carcinoma. The goal is to see how well the treatment works and how safely it can be given.
This study looks at how well a treatment called liposomal irinotecan works for people with advanced pancreatic cancer that has spread. You may qualify if you have already tried a chemotherapy drug called gemcitabine and it stopped working.
This trial tests a new combination of drugs (NC410 plus chemotherapy and nivolumab, with or without ipilimumab) for people with metastatic pancreatic cancer who haven't had treatment yet. The goal is to see if adding these immunotherapy agents can help shrink or control the tumor.
This trial compares two combinations of chemotherapy drugs for people with advanced pancreatic cancer whose first treatment stopped working. The study tests whether adding oxaliplatin and bevacizumab to liposomal irinotecan works better than a standard combination.
This trial tests a new liposomal form of irinotecan in combination with other drugs as a second or later treatment for people with advanced pancreatic cancer that continued to grow after prior irinotecan therapy. It aims to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a new form of chemotherapy (irinotecan liposome) combined with two other chemo drugs, compared to a standard treatment, for people with metastatic pancreatic cancer who haven't had chemo yet.
Hear when a new Metastatic Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.